Watch CRBU. Know when insiders buy.
One email the day a filing lands. Free.
CRBU
Caribou Biosciences, Inc.
1.37
−0.07 −4.86%
USD · close Sep 10
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
33
FLAG · shorts 33
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $146.9MP/E —DIV YIELD —FCF YIELD -65.19%REV TTM $10M +10.0%NET INCOME −$103.4MNET CASH —52W 1.37 – 2.84SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $1.5M | −43.8% | — | −$25.3M | −$24.3M | — | -0.24 | −$22.8M | $1K | −$22.8M | Aug 13 |
| Q1 2026 · Mar 31 | $2.4M | +1.9% | — | −$26.3M | −$25.1M | — | -0.26 | −$27M | $72K | −$27.1M | Aug 13 |
| Q4 2025 · Dec 31derived | $3.9M | +89.7% | — | −$28.5M | −$26.5M | — | -0.28 | −$20.8M | −$216K | −$20.6M | Mar 5 |
| Q3 2025 · Sep 30 | $2.2M | +8.6% | — | −$29.4M | −$27.5M | — | -0.30 | −$25.2M | $115K | −$25.3M | Nov 12 |
| Q2 2025 · Jun 30 | $2.7M | −23.0% | — | −$47.6M | −$54.1M | — | -0.58 | −$28.3M | $418K | −$28.7M | Aug 13 |
| Q1 2025 · Mar 31 | $2.4M | −3.1% | — | −$42.9M | −$40M | — | -0.43 | −$36.7M | $1M | −$37.8M | Aug 13 |
| Q4 2024 · Dec 31derived | $2.1M | −41.6% | — | −$38.9M | −$35.5M | — | -0.39 | −$35.5M | $518K | −$36M | Mar 5 |
| Q3 2024 · Sep 30 | $2M | −91.4% | — | −$38.2M | −$34.7M | — | -0.38 | −$32.7M | $673K | −$33.3M | Nov 12 |
| Q2 2024 · Jun 30 | $3.5M | — | — | −$43.5M | −$37.7M | — | -0.42 | −$32.9M | $2.2M | −$35.1M | Nov 12 |
| Q1 2024 · Mar 31 | $2.4M | — | — | −$46M | −$41.2M | — | -0.46 | −$37.2M | $1.4M | −$38.7M | Nov 12 |
| Q4 2023 · Dec 31derived | $3.6M | — | — | −$37.4M | −$34.5M | — | -0.40 | −$21.4M | $2.3M | −$23.7M | Mar 10 |
| Q3 2023 · Sep 30 | $23.7M | — | — | −$14.6M | −$10M | — | -0.12 | −$28.8M | $4.8M | −$33.5M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $11.2M | — | −$148.3M | −$148.1M | -1327.4% | -1.59 | −$111M | $1.4M | −$112.4M | — | — |
| FY2024 · to Dec 31 | $10M | — | −$166.6M | −$149.1M | -1491.9% | -1.65 | −$138.2M | $4.9M | −$143.1M | — | — |
| FY2023 · to Dec 31 | $34.5M | — | −$116.1M | −$102.1M | -296.1% | -1.38 | −$93.3M | $11.6M | −$104.9M | — | — |
| FY2022 · to Dec 31 | $13.9M | — | −$106.4M | −$99.4M | -717.8% | -1.64 | −$91M | $6.5M | −$97.4M | — | — |
| FY2021 · to Dec 31 | $9.6M | — | −$67M | −$66.9M | -697.3% | -2.11 | −$32.5M | $2.1M | −$34.6M | — | — |
| FY2020 · to Dec 31 | $12.4M | — | −$36.1M | −$34.3M | -277.6% | -4.01 | −$33.2M | $317K | −$33.5M | — | — |
Every number comes from Caribou Biosciences, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.